996 related articles for article (PubMed ID: 23408569)
1. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and natural history of Graves' orbitopathy in the XXI century.
Piantanida E; Tanda ML; Lai A; Sassi L; Bartalena L
J Endocrinol Invest; 2013 Jun; 36(6):444-9. PubMed ID: 23587873
[TBL] [Abstract][Full Text] [Related]
3. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
Bartalena L
J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
[TBL] [Abstract][Full Text] [Related]
4. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism.
Le Moli R; Malandrino P; Russo M; Lo Giudice F; Frasca F; Belfiore A; Vigneri R
Front Endocrinol (Lausanne); 2020; 11():367. PubMed ID: 32595602
[No Abstract] [Full Text] [Related]
6. Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism.
Wiersinga W; Žarković M; Bartalena L; Donati S; Perros P; Okosieme O; Morris D; Fichter N; Lareida J; von Arx G; Daumerie C; Burlacu MC; Kahaly G; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
Eur J Endocrinol; 2018 Jun; 178(6):635-643. PubMed ID: 29650691
[TBL] [Abstract][Full Text] [Related]
7. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
8. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
Perros P; Žarković M; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi A; Bournaud C; Brix TH; Covelli D; Ćirić S; Daumerie C; Eckstein A; Fichter N; Führer D; Hegedüs L; Kahaly GJ; Konuk O; Lareida J; Lazarus J; Leo M; Mathiopoulou L; Menconi F; Morris D; Okosieme O; Orgiazzi J; Pitz S; Salvi M; Vardanian-Vartin C; Wiersinga W; Bernard M; Clarke L; Currò N; Dayan C; Dickinson J; Knežević M; Lane C; Marcocci C; Marinò M; Möller L; Nardi M; Neoh C; Pearce S; von Arx G; Törüner FB
Br J Ophthalmol; 2015 Nov; 99(11):1531-5. PubMed ID: 25953846
[TBL] [Abstract][Full Text] [Related]
9. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy.
Elbers L; Mourits M; Wiersinga W
Thyroid; 2011 Mar; 21(3):279-83. PubMed ID: 21190446
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Graves' ophthalmopathy in patients with Graves' disease presenting to a referral centre in north India.
Reddy SV; Jain A; Yadav SB; Sharma K; Bhatia E
Indian J Med Res; 2014 Jan; 139(1):99-104. PubMed ID: 24604044
[TBL] [Abstract][Full Text] [Related]
11. Incidence and clinical presentation of moderate to severe graves' orbitopathy in a Danish population before and after iodine fortification of salt.
Laurberg P; Berman DC; Bülow Pedersen I; Andersen S; Carlé A
J Clin Endocrinol Metab; 2012 Jul; 97(7):2325-32. PubMed ID: 22518849
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Graves' Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study.
Khong JJ; Finch S; De Silva C; Rylander S; Craig JE; Selva D; Ebeling PR
J Clin Endocrinol Metab; 2016 Jul; 101(7):2711-20. PubMed ID: 27055083
[TBL] [Abstract][Full Text] [Related]
13. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
[TBL] [Abstract][Full Text] [Related]
14. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
[TBL] [Abstract][Full Text] [Related]
15. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
Krassas GE; Segni M; Wiersinga WM
Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
[TBL] [Abstract][Full Text] [Related]
16. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
[TBL] [Abstract][Full Text] [Related]
17. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.
García-Mayor RV; Álvarez-Vázquez P; Fluiters E; Valverde D; Andrade A
Endocrine; 2019 Feb; 63(2):316-322. PubMed ID: 30334140
[TBL] [Abstract][Full Text] [Related]
18. Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center.
Leo M; Menconi F; Rocchi R; Latrofa F; Sisti E; Profilo MA; Mazzi B; Albano E; Nardi M; Vitti P; Marcocci C; Marinò M
Thyroid; 2015 Mar; 25(3):347-51. PubMed ID: 25584927
[TBL] [Abstract][Full Text] [Related]
19. Radioactive iodine (RAI) treatment of hyperthyroidism is safe in patients with Graves' orbitopathy--a prospective study.
Król A; Koehler A; Nowak M; Paliczka-Cieślik E; Krajewska J; Kalemba M; Jurecka-Lubieniecka B; Hasse-Lazar K; Michalik B; Szpak-Ulczok S; Zarudzki Ł; Roskosz J; Jarząb B
Endokrynol Pol; 2014; 65(1):40-5. PubMed ID: 24549601
[TBL] [Abstract][Full Text] [Related]
20. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.
Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
